Solara gets CEP approval to manufacture Ibuprofen from Vishakhapatnam Facility

01 Nov 2022 Evaluate

Solara Active Pharma Sciences (Solara) has received ‘Certificate of Suitability’ (CEP) approval for its new state of the art multipurpose API manufacturing facility at Vishakhapatnam, Andhra Pradesh, for the manufacture of Ibuprofen API, from European Directorate for the Quality of Medicines (EDQM), the first international regulatory approval for this new facility.

With this key approval, Solara has CEP approval for two manufacturing facilities for Ibuprofen API, the other being its dedicated manufacturing facility located at Puducherry, India. Solara also expects series of other international regulatory approvals for its Vizag facility, including USFDA.

Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer.

Solara Active Pharma Share Price

551.50 1.15 (0.21%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×